Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

DAC Biotech to Discover Five ADCs in Partnership with Janssen Biotech

publication date: Sep 2, 2022

Hangzhou DAC Biotechnology will apply its ADC technology to develop up to five products for Janssen Biotech, a division of Johnson & Johnson. A 10-year-old ADC specialist, DAC’s ADC platform includes more than 50 novel intelligent linkers (including site-specific conjugation) and 100 small molecule cytotoxic drugs. DAC will receive an upfront payment, cost reimbursement and milestone payments, plus royalties on sales for each selected product. Johnson & Johnson Innovation will make an equity investment in DAC.  Specific details were not disclosed. The agreement was originally announced in June of this year. More details....

Stock Symbol: (NYSE: JNJ)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital